Happy Wednesday!

Ethereum has hit $4,700 and Standard Chartered thinks it could go to $7,500 this year — here’s what the bank is predicting.

BitMine has played no small part in ETH pushing close to a new all-time high. And the company isn’t done yet, judging by its $20 billion stock offering to buy more ETH.

Plus, if you’re interested in a biopharmaceutical company hitting milestones developing therapeutics to treat suicidal bipolar depression that aren’t lost on some on Wall Street, check out today’s sponsor. 

TOP STORY

ETH To $7,500 In 2025, Says Standard Chartered, As Ethereum ETFs Buy Over $500M Again

Standard Chartered has increased its base-case forecast for Ethereum to $7,500 by the end of 2025, citing stronger-than-expected demand from exchange-traded funds (ETFs) and heightened on-chain activity.

What Happened: The new projection comes less than two months after the bank outlined an $8,000–$9,000 bull case, which it now frames as upside potential rather than the central scenario.

In a note to clients, Geoff Kendrick, the bank's head of FX Research West and Digital Assets Research, said, "We think Ethereum will continue to benefit from the positive feedback loop between price, on-chain activity, and investor inflows."

He added that the updated forecast reflects "higher-than-expected ETF inflows and stronger on-chain activity."

Read the full scoop here. 

SPONSORED CONTENT

NRx Pharmaceuticals Makes Progress, And Wall Street Takes Notice

NRx Pharmaceuticals Inc. (NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, is hitting milestones that aren’t lost on some investment firms on Wall Street. 

D. Boral Capital and BTIG reiterated their buy ratings on NRx given the progress the company is making with its two drugs (NXT-101 and NXT-100) and its network of clinics to offer ketamine, transcranial magnetic stimulation (TMS) and other lifesaving therapies. 

Both investment firms have at least double-digit growth expectations on NRx’s stock, if not more. Potential catalysts include FDA drug approvals later this year and a regulation that could provide a clear edge over competitors.

NRX-100 recently received Fast Track designation for treating suicidal ideation in depression, including bipolar depression, supported by FDA-submitted trials showing significant, meaningful reductions, and expanding its addressable population tenfold.

To learn more about NRx Pharmaceuticals, click here.

This is a paid ad. Please see 17b disclosure here for more information.

QUICK N DIRTY

Bitcoin, Ethereum, Dogecoin, XRP are pumping again on Wednesday as ETH is approaching all-time highs: here’s what’s driving the market.

Metaplanet has reported earnings for Q2, and it turns out the company is now Asia’s biggest Bitcoin treasury company — here’s all you need to know about that.

Shiba Inu’s burn rate has exploded to over 40,000% and SHIB is up 5%: is it finally time for a new bull run?

SPECIAL EVENT

Your Next Big Fintech Breakthrough Starts Here

Looking for your next partnership, investor or spark of inspiration? On November 10, 2025, the Benzinga Fintech Day & Awards returns to NYC to connect the most influential names in financial technology. Meet innovators, decision-makers and investors who are actively shaping the next wave of fintech disruption. Featuring high-impact networking, cutting-edge insights and a prestigious awards ceremony — it’s the one fintech event you can’t afford to miss.

Join the innovators moving the industry forward — register now.

FINTECH FOCUS

Bitmine Plans $20 Billion Ethereum Blitz — Could ETH Hit $15,000?

Ethereum's next moonshot might be brewing — and it's not coming from a meme coin army, but from Bitmine Immersion Technologies Inc.'s boardroom.

The Cathie Wood, Peter Thiel and Tom Lee-backed crypto infrastructure company is reportedly planning to raise a staggering $20 billion for one purpose: to buy ETH.

That's double the scale of the last big corporate buying spree, which sent prices from $2,000 to $4,500, noted an X user. And if history rhymes, this time the jump could be seismic — with $15,000 ETH whispered as "programmed."

Read the full scoop here. 

BEFORE YOU GO

Were you forwarded this email? Click here to subscribe.

And be sure to check out our other newsletters:

Ring The Bell: Created for market enthusiasts by market enthusiasts, this daily newsletter delivers top stories, fast movers and hot trade ideas straight to your inbox. Subscribe here.

Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis and news. Subscribe here.

Tech Trends: Get the inside scoop on AI, the hottest gadgets and mind-blowing tech trends. Subscribe here.